A Phase 3 interventional study of 177Lu-TLX250 in ccRCC, Renal Cell Carcinoma (Kidney Cancer) and Renal Cell Carcinoma (RCC), sponsored by Telix Pharmaceuticals (Innovations) Pty Limited. Recruiting at 5 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-01.
Sponsored by Telix Pharmaceuticals (Innovations) Pty Limited (part of Telix Pharmaceuticals Limited) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 126 studies in Carcinoma, Renal Cell with a site in Australia — 23 open to participants now, 46 under way, 11 of them phase 3. Carcinoma, Renal Cell · Australia.
Among the 126 studies in Carcinoma, Renal Cell with a site in Australia, this one is the 101st largest by planned enrollment of the 119 interventional ones that give a count, is one of 7 that started in 2026, is one of 37 in phase 3, reaches primary completion later than 27 of the 45 other live ones, and was the 118th registered.
2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 397 are open to participants now.
Browse Carcinoma, Renal Cell studies →23 of the 126 studies in Carcinoma, Renal Cell with a site in Australia are open now. Recruiting first, the newest first:
Huahui Health · Sites in Australia, China
Ages 18–75
Merck Sharp & Dohme LLC · Sites in Australia, United States, Argentina and 16 more countries
Ages 18+
Bristol-Myers Squibb · Sites in Australia, United States, Argentina and 17 more countries
Ages 18+
Pfizer · Sites in Australia, United States, China and 3 more countries
Ages 18+
Incyte Corporation · Sites in Australia, United States, Belgium and 2 more countries
Ages 18+
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
126 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 56 · Phase 2 48 · Phase 3 37
First in 1998; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is close to the median of 43 across 1,569 interventional studies indexed under Carcinoma, Renal Cell.
Median enrollment 223 across the 119 interventional studies, 4,018 across the 2 observational. Of the 74 that completed or were terminated, 47 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
107 of 126 have an industry lead sponsor. The 10 most frequent:
This study is registered under Telix Pharmaceuticals (Innovations) Pty Limited, one of the names counted as Telix Pharmaceuticals Limited. Under that name alone:
Telix Pharmaceuticals (Innovations) Pty Limited is the lead sponsor of 22 studies on the registry; 9 are open to participants now.
Telix Pharmaceuticals Limited has 8 studies filed under Carcinoma, Renal Cell — fewer than ten, so there is no comparison to draw.
14 of the studies in Carcinoma, Renal Cell with a site in Australia that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03815643Phase 3EMD Serono Research & Development Institute, Inc.Avelumab Program Rollover Study | 2026-11-24 |
| NCT05678673Phase 3ExelixisStudy of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | 2026-12-15 |
| NCT07197580Phase 3Telix Pharmaceuticals (Innovations) Pty LimitedPhase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC | 2027-08-31 |
| NCT05468697Merck Sharp & Dohme LLCA Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024) | 2026-12-22 |
| NCT04140526OncoC4, Inc.Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 126 studies in Carcinoma, Renal Cell with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Multicenter Phase 3 study of 177Lu-TLX250 in adult participants with CAIX-expressing advanced, relapsed or recurrent clear cell renal cell carcinoma (ccRCC). Part 1 will evaluate two dosing regimens to determine the recommended Phase 3 dose (RP3D). Part 2 will compare 177Lu-TLX250 with investigator's choice of monotherapy aligned with Australian standard-of-care.
This is a randomized, open-label, multi-center 3 study evaluating the safety and efficacy of 177Lu-TLX250, a CAIX-targeting radioligand therapy, in adult participants with advanced, relapsed or recurrent clear cell renal cell carcinoma (ccRCC).
The study consists of two parts:
The objective of Part 1 is to determine the recommended Phase 3 dose (RP3D) for use in Part 2.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Bone Marrow:
Liver Function:
Renal Function:
Exclusion Criteria:
have any of the following:
be currently receiving or have received:
have a history of concurrent with a of ≤ 2 years or requirement of systemic anti-cancer therapy or requirement of local therapy that would confound study results; however; participants with the following malignancies can be enrolled into the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
3 infusions of 1887 MBq 177Lu-TLX250 at 8-week intervals or 6 infusions of 1258 MBq 177Lu-TLX250 at 4-week intervals (fractionation of 3 doses of 2516 MBq)
Radiation: 177Lu-TLX250
6 infusions of 1258 MBq 177Lu-TLX250 at 4-week intervals
Radiation: 177Lu-TLX250
3 infusions of 177Lu-TLX250 at 8-week intervals or 6 infusions 177Lu-TLX250 at 4-week intervals
Also known as: TLX250-Tx, 177Lu girentuximab tetraxetan
Dose Optimization -safety and tolerability
Part 1 of the study is being done to identify the best dose to use for Part 2 of the study. Assessing adverse events of special interest (AESIs), incidence and severity of treatment-emergent adverse events (TEAEs) and frequency, severity according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) V5.0, seriousness, and relationship of study treatment will be assessed. Laboratory abnormalities will be assessed according to the NCI CTCAE V5.0.
Time frame: Through study completion, an average of 1.5 years
Efficacy- median mPFS
Primary objective for Part 2 of the study and secondary objective for Part 1. Monitoring disease progression according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1).
Time frame: Through study completion, an average of 2 years
Monitoring OS (Overall Survival)
Time from the date of randomization to death from any cause
Time frame: Through study completion, an average of 2 years
Monitoring ORR (Objective Response Rate)
Proportion of participants achieving confirmed objective response rate (ORR), i.e., complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) as assessed by a blinded independent central review (BICR)
Time frame: Through study completion, an average of 2 years
Monitoring DoR (Duration of Response)
Time from the first documentation of objective response, i.e., complete response (CR) or partial response (PR) to the first documentation of disease progression or death due to any cause as assessed by blinded independent central review (BICR)
Time frame: Through study completion, an average of 2 years
Monitoring DCR (Disease control Rate)
The proportion of participants achieving confirmed objective response, i.e., complete response (CR), partial response (PR), or stable disease (SD) per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR)
Time frame: Through study completion, an average of 2 years
Evaluate blood radioactive PK parameter- Cmax (maximum plasma concentration)
Gamma-counting blood radioactivity will be used to derive this pharmacokinetics parameter
Time frame: Treatment period (4 months)
Evaluate blood radioactive PK parameter- AUCinf (area under blood concentration time curve from zero to infinity)
Gamma-counting blood radioactivity will be used to derive this pharmacokinetics parameter.
Time frame: During Treatment (4 months)
Evaluate blood radioactive PK parameter- t1/2 (Terminal half-life)
Gamma-counting blood radioactivity will be used to derive this pharmacokinetics parameter.
Time frame: During Treatment (4 months)
Evaluate blood radioactive PK parameter- CL (Clearance)
Gamma-counting blood radioactivity will be used to derive this pharmacokinetics parameter.
Time frame: During Treatment (4 months)
Tumor and Organ-specific 177Lu-TLX250 absorbed radiation values
Images-radiation values for tumor and lesions will be measured and analyzed after first and second administration of 177Lu-TLX250.
Time frame: During Treatment (4 months)
TAC for tumor and organ
Time Activity Curves (TAC) will be used to derive time integrated activity parameters in tumor and organ
Time frame: During Treatment (4 months)
Tumor- and organ-specific 177Lu-TLX250 residence time
Residence time of 177Lu-TLX250 in tumor and organs will be derived and interpreted
Time frame: During Treatment (4 months)
Identification of dose-limiting organ(s)
Absorbed dose will be compared to maximal dosimetry threshold for each organ to evaluated the dose limiting organ
Time frame: During Treatment (4 months)
Characterize health utility as measured using the European Quality of Life 5 Dimensions 5 Level Version (EuroQoL EQ-5D-5L)
Health utility scores from the European Quality of Life 5 Dimensions 5 Level Version (EuroQoL EQ-5D-5L) questionnaire
Time frame: Through study completion, an average of 2 years
Change from Baseline in EORTC QLQ-C30 Physical Functioning
Assessed using the EORTC QLQ-C30 questionnaire to evaluate physical functioning.
Time frame: Through study completion, an average of 2 years
Change from Baseline in EORTC QLQ-C30 Global Health Status/HRQoL
Assessed using the EORTC QLQ-C30 questionnaire to evaluate overall health-related quality of life.
Time frame: Through study completion, an average of 2 years
Change from Baseline in FKSI-DRS Subscale
Assessed using the FKSI-DRS (Functional Assessment of Cancer Therapy - Kidney Symptom Index) to evaluate disease-related symptoms.
Time frame: Through study completion, an average of 2 years
Incidence and Severity of AESIs and TEAEs
Adverse events will be assessed and graded per NCI-CTCAE v5.0 criteria.
Time frame: Through study completion, an average of 2 years
Dosing Delays Due to 177Lu-TLX250-Related TEAEs
Number of dosing delays attributed to TEAEs related to 177Lu-TLX250.
Time frame: Through study completion, an average of 2 years
Activity Level Reductions Due to 177Lu-TLX250-Related TEAEs
Number of participants with reduced activity levels due to TEAEs related to 177Lu-TLX250.
Time frame: Through study completion, an average of 2 years
Evaluation of Immunogenicity (HACA)
Incidence of HACA positivity, overall per treatment group, and per visit (to track incidence over time)
Time frame: Through study completion, an average of 2 years
Evaluation of HACA on PK/Biodistribution
Evaluate any correlation of incidence of HACA positivity to changes in PK/Biodistribution per treatment group
Time frame: Through study completion, an average of 2 years
Evaluation of HACA on efficacy/safety
Evaluate any correlation of incidence of HACA positivity to changes in efficacy/safety end points per treatment group
Time frame: Through study completion, an average of 2 years
Characterization of HACA neutralizing activity
For confirmed positive HACA samples, incidence of nAb positivity, overall per treatment group, and per visit (to track incidence over time), as applicable
Time frame: Through study completion, an average of 2 years
Evaluation of nAb on PK/Biodistribution
Evaluate any correlation of incidence of nAb positivity to changes in PK/Biodistribution per treatment group
Time frame: Through study completion, an average of 2 years
Evaluation of nAB on efficacy/safety
Evaluate any correlation of incidence of nAb positivity to changes in efficacy/safety end points per treatment group
Time frame: Through study completion, an average of 2 years
Evaluate Radiation Exposure-Response parameter- normalized absorbed dose to individual organs (mGy/MBq)
Evaluate relationship between normalized absorbed dose to individual organs with DCR, ORR and incidence and severity of AESI
Time frame: Through study completion, an average of 2 years
Evaluate Radiation Exposure-Response parameter- AUC
Evaluate relationship between AUC to individual organs with DCR, ORR and incidence and severity of AESI.
Time frame: Through study completion, an average of 2 years
Evaluate Radiation Exposure-Response parameter- Cmax
Evaluate relationship between Cmax to individual organs with DCR, ORR and incidence and severity of AESI.
Time frame: Through study completion, an average of 2 years
Evaluate Radiation Exposure-Response parameter- normalized absorbed dose to tumors (mGy/MBq)
Evaluate relationship between normalized absorbed dose to tumor with DCR, ORR and incidence and severity of AESI.
Time frame: Through study completion, an average of 2 years
Plan to share: No — We have opted not to share individual participant data due to concerns regarding participant privacy and the absence of explicit consent for data sharing in the original trial protocol.
Started Mar 2026 (actual). Primary completion is estimated for Aug 2027, 17 months after the start.
Of 35 industry-sponsored phase 3 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 59. This study's planned 17 months is below that.
Counting every sponsor, half of 61 studies reached it within 56 months; a quarter within 42 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Telix Pharmaceuticals (Innovations) Pty Limited →